Maxime C D Soumeillant

Maxime C D Soumeillant is a notable inventor based in Princeton, NJ, specializing in innovative processes for pharmaceutical compounds. He holds two patents that contribute significantly to the field of medicinal chemistry. His work focuses on improving the synthesis of compounds that are currently undergoing clinical trials for various diseases.

Latest Patents

One of his latest patents is titled "Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3)pyridazine-3-carboxamide." This invention relates to an enhanced method for synthesizing a compound that is in clinical trials for treating autoimmune and auto-inflammatory diseases, including psoriasis. Another significant patent is for the "Process for the preparation of N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide." This invention also focuses on an improved synthesis process for a complex pharmaceutical compound.

Career Highlights

Maxime C D Soumeillant is currently employed at Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His work at this prestigious organization allows him to contribute to the development of innovative therapies that address critical health challenges.

Collaborations

Throughout his career, Maxime has collaborated with talented professionals, including Bahar Inankur and Sergei Kolotuchin. These collaborations have fostered a creative environment that enhances the development of groundbreaking pharmaceutical processes.

Conclusion

Maxime C D Soumeillant is a distinguished inventor whose contributions to pharmaceutical processes are paving the way for new treatments. His innovative work continues to impact the field positively, showcasing the importance of advancements in medicinal chemistry.

Profile summary based on public USPTO records.